Drug-eluting stents: current issues
January 2005
Article
| Related Files |
|---|
View PDF Version
(16392222.pdf, 0.2MB) |
Early stent thrombosis occurs in about 1% to 1.5% of patients with drug-eluting stents, very similar to the rate with bare-metal stents. Late stent thrombosis is more of a concern with drug-eluting stents, with an incidence of at least 0.35%. I would urge caution if you feel you have to stop antiplatelet therapy in patients with drug-eluting stents. While neointima formation peaks at 6 months and then may actually regress with bare-metal stents, it continues to grow with drug-eluting stents--although this process appears to plateau by 4 years with sirolimus. With the others, we have to wait and see. We still don't know the best drug-eluting stent. Trials are under way to compare stents with surgery, and the future brings the arrival of a number of exciting new devices and approaches that are now entering clinical trials.
- Humans
- Incidence
- *Stents
- Coronary Vessels/*surgery
- *Blood Vessel Prosthesis
- Graft Occlusion, Vascular/epidemiology/prevention & control
- *Coated Materials, Biocompatible
- Blood Vessel Prosthesis Implantation/*instrumentation
- Myocardial Ischemia/*surgery
- stent
- patient
- stent thrombosis
- thrombosis
- drug-eluting stents
- drug-eluting
- antiplatelet therapy
- month
- sirolimus-eluting
- angiographic stent thrombosis
- therapy
- sirolimus-eluting stents
- bare-metal
- trial
- study
- incidence
- cardiology
- aspirin
- antiplatelet
- drug-eluting stent
